NLGN3 and central nervous system cancer: To directly assess this hypothesis, we treated in vitro cell cultures of glioma cells with recombinant NLGN3 ectodomain proteins for one hour, collected the conditioned medium, and performed western blot analysis using antibodies against the CSPG4 N-terminus (Fig. 2a).